Scott Gottlieb has bought stock on 4 days since Jan 2020

Scott Gottlieb, MD, is a physician, investor, and healthcare policy expert who serves on the Board of Directors of Illumina, Inc. and was elected non-executive Chair of Illumina’s Board in 2025.( He originally joined Illumina’s board in February 2020 and has since been an influential corporate insider, bringing deep regulatory and clinical experience to the company’s leadership.( Dr. Gottlieb is also a Partner (special partner) at the venture capital firm New Enterprise Associates (NEA) and a Senior Fellow at the American Enterprise Institute (AEI), where his work focuses on medical innovation, public health, and regulatory policy.(

From 2017 to 2019, Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), having previously held several senior roles at the agency, including Deputy Commissioner for Medical and Scientific Affairs and Director of Medical Policy Development.( In addition to Illumina, he serves on the boards of Pfizer Inc., Tempus AI, and other life sciences and healthcare companies, and is an elected member of the National Academy of Medicine.( He holds a BA in economics from Wesleyan University and a medical degree from Mount Sinai School of Medicine, where he also completed his residency in internal medicine.(

Written by Perplexity from public sources.